Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions.

Abstract

Our results suggest that detecting EGFR mutations in cells from malignant pleural effusions is a feasible adjunct method to finding the subgroup with favorable response to gefitinib therapy among patients with advanced NSCLC.